-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Ezetimibe) in Hypercholesterolemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Atorvastatin + Ezetimibe) in Hypercholesterolemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Atorvastatin + Ezetimibe) in Hypercholesterolemia Drug Details: Atorvastation in combination with...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Ezetimibe) in Hyperlipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Atorvastatin + Ezetimibe) in Hyperlipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Atorvastatin + Ezetimibe) in Hyperlipidemia Drug Details: Atorvastation in combination with...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rosuvastatin ER in Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rosuvastatin ER in Dyslipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rosuvastatin ER in Dyslipidemia Drug Details: Rosuvastatin extended-release capsule (LYN-047) is under...
-
Thematic Analysis
NewMining M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Mining Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Ezetimibe) in Hyperlipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Atorvastatin + Ezetimibe) in Hyperlipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Atorvastatin + Ezetimibe) in Hyperlipidemia Drug Details:Atorvastation in combination with ezetimibe is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Ezetimibe) in Hypercholesterolemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Atorvastatin + Ezetimibe) in Hypercholesterolemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Atorvastatin + Ezetimibe) in Hypercholesterolemia Drug Details:Atorvastation in combination with ezetimibe is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Fluconazole + Minocycline) in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Atorvastatin + Fluconazole + Minocycline) in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Atorvastatin + Fluconazole + Minocycline)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Fluconazole + Minocycline) in Relapsing Multiple Sclerosis (RMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Atorvastatin + Fluconazole + Minocycline) in Relapsing Multiple Sclerosis (RMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Atorvastatin + Fluconazole + Minocycline) in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Evolocumab in Hypercholesterolemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Evolocumab in Hypercholesterolemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Evolocumab in HypercholesterolemiaDrug Details: Evolocumab (AMG-145, Repatha) is a monoclonal antibody acts as lipid...
-
Company Profile
NewFerring International Center SA – Company Profile
Ferring International Center SA (Ferring), a subsidiary of Ferring Holding SA research, develops and markets pharmaceutical products. The company offers products in the fields of reproductive health, endocrinology, gastroenterology, urology, and orthopedics. Its major products include Rekovelle (follitropin delta), for controlled ovarian stimulation; Menopur (HP-hMG) for female and male infertility; and Firmagon (degarelix) for prostate cancer. Its pipeline products encompass rHCG for Triggering FFM and rFSH for male infertility for infertility; FE 202767 for Lactation; RBX2660 enema for difficile infection...
Add to Basket